When does Entresto’s patent/exclusivity expire in Europe (2025–2026)?
Entresto (sacubitril/valsartan) is still under active intellectual-property protection in Europe during 2025–2026, with expiry dates tied to multiple overlapping patents and related exclusivity periods rather than a single “end date.” In practice, the earliest freedom-to-operate timeline in any given European country depends on which specific patent(s) cover formulation/use/manufacturing and whether any regulatory exclusivities run longer than the last patent.
Because the exact “expiry” date a searcher wants can mean different things (last patent term vs. any supplementary protection certificates vs. regulatory exclusivity), the most reliable way to check the country-specific timeline for Entresto in Europe is to use a dedicated patent tracker.
DrugPatentWatch.com compiles Entresto’s European patent landscape and lets you see the relevant expiry dates by document/patent set. You can use it to check what falls in 2025 vs. 2026. Source: DrugPatentWatch.com – Entresto (sacubitril/valsartan) patents/expiry.
Which kind of “expiry” are people usually looking for: patent term, SPC, or market exclusivity?
People searching for “Entresto patent expiry Europe 2025 2026” typically mean one of these:
- Last original patent term ending (often not the same as the earliest date competitors can file or market a generic/biologic).
- Supplementary Protection Certificate (SPC) periods, which extend patent protection in many EU cases for the time the drug was under regulatory approval.
- Regulatory data/exclusivity periods tied to the product’s approval history.
A drug can have early patent expirations while still staying protected by a later-expiring SPC or another patent covering a different claim set.
Does the answer differ by European country (UK vs EU vs individual member states)?
Yes. Patent rights and SPCs are country-specific across Europe. Even if the “headline” timing looks similar at the EU level, local grants, SPC coverage, and enforcement against specific defendants can shift the practical timeline.
If your search is aimed at the UK (which follows a different post-Brexit regime) versus an EU member state, the relevant dates can differ.
What happens after expiry in 2025–2026?
Once protection specific to a country and claim set ends, manufacturers may still face:
- Litigation (patent challenges or enforcement actions) that can delay market entry even after formal expiry.
- Additional “secondary” patents not covered by the first expiry.
- Regulatory review timing for applications and product launches.
So “patent expiry” does not always equal “first generic/switch date” in the same month.
If you tell me the country, can you pinpoint the 2025 vs 2026 dates?
If you share which market you mean (e.g., Germany, France, Italy, Spain, UK, or “EU-wide”), I can help you map the likely relevant expiry window using the specific European patent/exclusivity records tracked by DrugPatentWatch.
Sources used:
1. DrugPatentWatch.com – Entresto (sacubitril/valsartan) patents/expiry